Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771639 | 0.81 | CNR2 (0.53) | NAMPTCNR2 | |
| SCHEMBL17689403 | 0.81 | HTR2A (0.55) | NAMPTCNR2TXNRD1AKT1PIK3CA | |
| SCHEMBL15232716 | 0.80 | HTR2A (0.51) | NAMPTKDM4ESMN1; SMN2HTR2A | |
| SCHEMBL5755791 | 0.80 | CA1 (0.55) | KDM4ESMN1; SMN2HTR2A | |
| SCHEMBL15231711 | 0.78 | HTR2A (0.48) | NAMPTCNR2TXNRD1HTR2A | |
| SCHEMBL21878482 | 0.77 | QDPR (0.57) | — | |
| SCHEMBL160743 | 0.76 | LOXL2 (0.51) | NAMPTKDM4ESMN1; SMN2HTR2A | |
| SCHEMBL18711258 | 0.75 | MEN1 (0.50) | NAMPTCNR2TXNRD1CCR5AKT1 | |
| SCHEMBL15232842 | 0.75 | HTR2A (0.49) | NAMPTHTR2A | |
| SCHEMBL14538161 | 0.75 | ALDH1A1 (0.48) | NAMPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | Valo Health, LLC | 2020-06-30 | — | — | US | disclosed |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | VALO HEALTH, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | STS, SQOR, SULT1E1 | NAMPT 459/4885KDM4E 594/4885SMN1; SMN2 346/4885 |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | STS, SULT1E1, CBS | NAMPT 759/4885KDM4E 661/4885SMN1; SMN2 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.